Abdelrahim Alqudah1, Muna Oqal2, Ahmad Al-Samdi3, Esam Qnais4, Mohammed Wedyan4, Majd Abu Gneam1, Roaa Alnajjar1, Manar Alajarmeh1, Elaf Yousef1, Omar Gammoh5. 1. Department of clinical pharmacy and pharmacy practice, Faculty of pharmaceutical sciences, The Hashemite University, Zarqa, Zarqa, P.O box 330127, Zarqa 13133, Jordan, Jordan. 2. Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmaceutical sciences, The Hashemite University, Zarqa, Zarqa, 13133, Jordan. 3. Department of Adult Health Nursing, Princess Salma Faculty of Nursing, Al al-Bayt University, Al-Mafraq, Zarqa, 13133, Jordan. 4. Department of Biology and Biotechnology, Faculty of Science, Hashemite University, Zarqa, Zarqa, 13133, Jordan. 5. Department of Clinical Pharmacy and Pharmacy Practice, Yarmouk University, Irbid, Zarqa, 13133, Jordan.
Abstract
Background: Sodium/glucose cotransporter 2 (SGLT2) inhibitors are a new class of oral anti-diabetic drugs which improve glycaemic control in type 2 diabetes mellitus (T2DM) by preventing the kidney from reabsorbing glucose back to blood. Community pharmacists have long-term relationships with most of their chronic patients, so they play a key role in care for people with diabetes. Therefore, the objective of this study was to assess pharmacists' knowledge and practice towards SGLT2 inhibitors. Thus, improving pharmacists' knowledge about this group of medications could improve the treatment outcome of people with diabetes. Methods: A cross-sectional study was conducted to meet the study objectives. A convenience sample of 348 community pharmacists in Jordan was recruited. knowledge and practice were assessed using a self-administered questionnaire created for the purpose of this study. Results: A total of 400 community pharmacists were reached, of whom 348 answered the survey (response rate 87%). The results indicated that SGLT2 inhibitors knowledge score among community pharmacists in Jordan was 6.61 (out of 12). Factors like age, gender, location of the pharmacy, years of pharmacists' experience had no effect on knowledge score; however, pharmacists who attended training courses on diabetes had higher knowledge scores. Additionally, pharmacists' dispensing practice toward SGLT2 inhibitors had insufficient knowledge, such as lack of knowledge about the superiority of SGLT2 inhibitors over other anti-diabetics and inability to give the best advice to patients. Conclusions: Our findings reflect a moderate knowledge among community pharmacists about SGLT2 inhibitors which may negatively affect the patients' outcome; thus, continuous education for the pharmacists is essential. Copyright:
Background: Sodium/glucose cotransporter 2 (SGLT2) inhibitors are a new class of oral anti-diabetic drugs which improve glycaemic control in type 2 diabetes mellitus (T2DM) by preventing the kidney from reabsorbing glucose back to blood. Community pharmacists have long-term relationships with most of their chronic patients, so they play a key role in care for people with diabetes. Therefore, the objective of this study was to assess pharmacists' knowledge and practice towards SGLT2 inhibitors. Thus, improving pharmacists' knowledge about this group of medications could improve the treatment outcome of people with diabetes. Methods: A cross-sectional study was conducted to meet the study objectives. A convenience sample of 348 community pharmacists in Jordan was recruited. knowledge and practice were assessed using a self-administered questionnaire created for the purpose of this study. Results: A total of 400 community pharmacists were reached, of whom 348 answered the survey (response rate 87%). The results indicated that SGLT2 inhibitors knowledge score among community pharmacists in Jordan was 6.61 (out of 12). Factors like age, gender, location of the pharmacy, years of pharmacists' experience had no effect on knowledge score; however, pharmacists who attended training courses on diabetes had higher knowledge scores. Additionally, pharmacists' dispensing practice toward SGLT2 inhibitors had insufficient knowledge, such as lack of knowledge about the superiority of SGLT2 inhibitors over other anti-diabetics and inability to give the best advice to patients. Conclusions: Our findings reflect a moderate knowledge among community pharmacists about SGLT2 inhibitors which may negatively affect the patients' outcome; thus, continuous education for the pharmacists is essential. Copyright:
Authors: Lori MacCallum; Annalise Mathers; Jamie Kellar; Jeremy Rousse-Grossman; Julia Moore; Gary F Lewis; Lisa Dolovich Journal: Res Social Adm Pharm Date: 2020-04-09
Authors: K Ajlouni; A Batieha; H Jaddou; Y Khader; N Abdo; M El-Khateeb; D Hyassat; D Al-Louzi Journal: Diabet Med Date: 2019-01-25 Impact factor: 4.359
Authors: Silvio E Inzucchi; Richard M Bergenstal; John B Buse; Michaela Diamant; Ele Ferrannini; Michael Nauck; Anne L Peters; Apostolos Tsapas; Richard Wender; David R Matthews Journal: Diabetes Care Date: 2015-01 Impact factor: 19.112
Authors: Amina M Bagher; Thikryat Neamatallah; Ghadeer Balto; Lina Almikhy; Sara S Almutairi; Mohammed O Abushal; Khlood Baghlaf; Sara M Bagher Journal: Saudi Pharm J Date: 2020-12-30 Impact factor: 4.330